.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Moodys
Cerilliant
Mallinckrodt
Teva
Harvard Business School
Healthtrust
McKinsey
McKesson
US Department of Justice
US Army

Generated: July 24, 2017

DrugPatentWatch Database Preview

Abbott Company Profile

« Back to Dashboard

What is the competitive landscape for ABBOTT, and what generic alternatives to ABBOTT drugs are available?

ABBOTT has one hundred and fourteen approved drugs.

There are six US patents protecting ABBOTT drugs.

There are eighty-three patent family members on ABBOTT drugs in thirty-six countries.

Summary for Applicant: Abbott

Patents:6
Tradenames:92
Ingredients:65
NDAs:114
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbott
CEPHALOTHIN SODIUM
cephalothin sodium
INJECTABLE;INJECTION062548-001Sep 11, 1985DISCNNoNo► Subscribe► Subscribe► Subscribe
Abbott
ERYTHROCIN
erythromycin lactobionate
INJECTABLE;INJECTION062586-001Jan 4, 1988DISCNNoNo► Subscribe► Subscribe► Subscribe
Abbott
AMINOSYN 3.5% W/ DEXTROSE 25% IN PLASTIC CONTAINER
amino acids; dextrose
INJECTABLE;INJECTION019118-001Oct 11, 1984DISCNNoNo► Subscribe► Subscribe► Subscribe
Abbott
A-METHAPRED
methylprednisolone sodium succinate
INJECTABLE;INJECTION089574-001Feb 22, 1991DISCNNoNo► Subscribe► Subscribe► Subscribe
Abbott
AMINOSYN 3.5% M IN PLASTIC CONTAINER
amino acids; magnesium acetate; phosphoric acid; potassium acetate; sodium chloride
INJECTABLE;INJECTION018804-002May 15, 1984DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Abbott

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbott
HYTRIN
terazosin hydrochloride
CAPSULE;ORAL020347-001Dec 14, 1994► Subscribe► Subscribe
Abbott
HYTRIN
terazosin hydrochloride
TABLET;ORAL019057-001Aug 7, 1987► Subscribe► Subscribe
Abbott
HYTRIN
terazosin hydrochloride
TABLET;ORAL019057-004Aug 7, 1987► Subscribe► Subscribe
Abbott
PROSOM
estazolam
TABLET;ORAL019080-002Dec 26, 1990► Subscribe► Subscribe
Abbott
HYTRIN
terazosin hydrochloride
CAPSULE;ORAL020347-001Dec 14, 1994► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for ABBOTT drugs

Drugname Dosage Strength Tradename Submissiondate
ritonavir
Capsules100 mg
NORVIR
10/31/2012
ritonavir
Tablets100 mg
NORVIR
12/21/2010
sibutramine hydrochloride
Capsules10 mg and 15 mg
MERIDIA
8/14/2009
fenofibrate
Tablets48 mg
TRICOR
7/1/2008
fenofibrate
Tablets145 mg
TRICOR
10/19/2007

Non-Orange Book Patents for Abbott

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,596,317 Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it► Subscribe
8,343,540Process for producing fenofibrate tablets► Subscribe
8,329,214Process for producing fenofibrate tablets► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Abbott Drugs

Country Document Number Estimated Expiration
Turkey9901660► Subscribe
Cyprus2513► Subscribe
Spain2263714► Subscribe
Ukraine61096► Subscribe
Estonia04042► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Abbott Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
90020-1Sweden► SubscribePRODUCT NAME: SACUBITRIL AND VALSARTAN, AS SACUBITRIL VALSARTAN SODIUM SALT COMPLEX, I.E. TRISODIUM 3-((1S,3R)-1-BIPHENYL-4-YLMETHYL-3- ETHOXYCARBONYL-1-BUTYLCARBAMOYL)PROPIONATE-(S)-3-METHYL-2- (PENTANOYL2-(TETRAZOL-5-YLATE)BIPHENYL-4- YLMETHYLAMINO)BUTYRATE HEMIPENTAHYDRATE; REG. NO/DATE: EU/1/15/1058 20151123
C/GB01/008United Kingdom► SubscribePRODUCT NAME: 1-(((3-(2-(DIMETHYLAMINO)ETHYL)INDOL-5-YL)METHYL)SULFONYL)PYRROLIDINE GENERIC NAME ALMOTRIPTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, ESPECIALLY AS ALMOTRIPTAN D,L - HYDROGEN MALATE; REGISTERED: ES 62.877 19991223; UK PL 16973/0005 20001026
C/GB01/053United Kingdom► SubscribePRODUCT NAME: SIBUTRAMINE HYDROCHLORIDE MONOHYDRATE; REGISTERED: DE 41531.00.00 19990114; DE 41531.01.00 19990114; DE 41533.00.00 19990114; DE 41533.01.00 19990114; CH IKS 54770 19990113; UK PL 0169/0129 20010511; UK PL 0169/0130 20010511
C/GB11/045United Kingdom► SubscribePRODUCT NAME: FINGOLIMOD, I.E. 2-AMINO-2-(2-(4-OCTYLPHENYL)ETHYL)PROPANE-1,3-DIOL, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/11/677/001 20110317; UK EU/1/11/677/002 20110317; UK EU/1/11/677/003 20110317; UK EU/1/11/677/004 20110317
00522Netherlands► SubscribePRODUCT NAME: FENTANYL EN DOSERINGSAPPLICATOR; REG. NO/DATE: EU/2/11/127/001 20111006
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

McKinsey
Accenture
QuintilesIMS
US Army
Fish and Richardson
Citi
McKesson
Cerilliant
Medtronic
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot